Scotiabank has recently initiated BridgeBio Pharma Inc (BBIO) stock to Sector Outperform rating, as announced on October 16, 2024, according to Finviz. Earlier, on October 3, 2024, Oppenheimer had initiated the stock to Perform. Piper Sandler also initiated Overweight rating with a price target of $46. Additionally, Raymond James resumed Outperform rating on March 21, 2024, with a target price of $45. BMO Capital Markets analysts, in their report published on January 31, 2024, also initiated Market Perform rating and set a price target of $37 for BridgeBio Pharma Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
BridgeBio Pharma Inc (BBIO) Stock Trading Recap
On Monday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $31.03 which represents a decrease of $-3.18 or -9.30% from the prior close of $34.21. The stock opened at $33.73 and touched a low of $31 during the day, reaching a high of $33.8. The volume of shares traded was 5.10 million exceeding the average volume of 2.43 million.
Sponsored
BBIO Stock Performance and Moving Averages
In recent trading, BridgeBio Pharma Inc (BBIO) stock price has shown some volatility, fluctuating -15.38% over the last five trades and 13.08% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 18.53%, and it has gained 30.43% in the previous three months. Currently, BBIO is trading at -7.82%, 4.69%, and 14.43% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, BBIO, a Healthcare sector stock, is trading -24.39% below its 52-week high but remains 43.52% above its 52-week low. The Average True Range (ATR) (14 days) of 1.73 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
BridgeBio Pharma Inc’s Profitability and Valuation Ratios
BridgeBio Pharma Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of -244.62% and a profit margin of -201.53%, with a gross margin of 18.53%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, BridgeBio Pharma Inc’s market capitalization stands at $5.86 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 26.93, reflecting the market’s valuation of the company’s sales.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 21.49% of BridgeBio Pharma Inc (BBIO)’s shares, while financial institutions hold 75.74%.
Notable insider trades include VIKING GLOBAL INVESTORS LP, 10% Owner at BridgeBio Pharma Inc (BBIO), who sold 3065616 shares on Jan 31 ’25, at $34.9 each, totaling $106.99 million. On Jan 28 ’25, STEPHENSON BRIAN C, Secretary, Treasurer & CFO, sold 68000 shares for $36.29 each, amounting to $2.47 million. Additionally, on Jan 28 ’25, Kumar Neil sold 326932 shares at $36.29 each, generating $11.86 million.